Equity Profile

EW

Edwards Lifesciences Corporation

Health CareHealth Care Equipment$53.4B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Edwards Lifesciences Corporation (EW) specializes in heart valve therapies and critical care monitoring. As a key player in the health care equipment sector, its innovations are crucial for improving patient outcomes in cardiovascular care.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability, reflecting the company's ability to generate earnings for shareholders.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market share and meet increasing demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

EW Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+87.79%

Avg Stock Reaction

-0.42%

Last Quarter Recap

In Q1-2026, Edwards Lifesciences reported an EPS of $0.78, exceeding expectations by 7.59%. Despite the positive surprise, the stock fell 2.22% the following day, indicating market caution.

Management Promises & Guidance

Continued focus on innovation in heart valve therapies.
Commitment to expanding global market presence.
Ongoing investment in research and development.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a strong track record of beating EPS estimates but recent stock reactions have been tepid.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if revenue growth does not meet expectations, it could raise concerns about market saturation and competitive pressures.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for heart valve therapies this quarter?

This figure will be crucial in assessing the company's market position and ability to capture demand.

Will management provide guidance on new product launches?

Insights into upcoming products could significantly impact future revenue and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product innovations on revenue growth this quarter.

Supporting Evidence

Historical EPS beat rate of 88% suggests strong operational performance.

Recent trends in heart disease treatments indicate a growing market for Edwards' products.

Options pricing indicates higher volatility than historical averages, suggesting investor uncertainty.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how well Edwards can sustain its growth trajectory amidst increasing competition.

Bull Confirmed If

A revenue growth rate of over 10% would confirm strong demand and market expansion.

Bear Confirmed If

If revenue growth falls below 5%, it could indicate challenges in maintaining market share.

Pre-Earnings Positioning

Options Market

Implied Move

±5.93%

Historical Avg

±0.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±5.9% while EW has averaged ±0.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

32.1%

Calls (397K)P/C Ratio: 0.49Puts (340K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edwards beats expectations, history suggests a potential stock increase of around 0.96%, confirming strong demand.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors will look for management commentary on future growth.

Miss

A miss could result in a decline, with historical patterns indicating a potential drop of around 0.33%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth for heart valve therapies.
2Insights into upcoming product launches and their expected impact.
3Management's commentary on competitive pressures in the market.
4Updates on international market expansion efforts.
5Any changes to long-term guidance or strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Calix, Inc.

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability, reflecting the company's ability to generate earnings for shareholders.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market share and meet increasing demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

EW Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+87.79%

Avg Stock Reaction

-0.42%

Last Quarter Recap

In Q1-2026, Edwards Lifesciences reported an EPS of $0.78, exceeding expectations by 7.59%. Despite the positive surprise, the stock fell 2.22% the following day, indicating market caution.

Management Promises & Guidance

Continued focus on innovation in heart valve therapies.
Commitment to expanding global market presence.
Ongoing investment in research and development.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a strong track record of beating EPS estimates but recent stock reactions have been tepid.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if revenue growth does not meet expectations, it could raise concerns about market saturation and competitive pressures.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for heart valve therapies this quarter?

This figure will be crucial in assessing the company's market position and ability to capture demand.

Will management provide guidance on new product launches?

Insights into upcoming products could significantly impact future revenue and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product innovations on revenue growth this quarter.

Supporting Evidence

Historical EPS beat rate of 88% suggests strong operational performance.

Recent trends in heart disease treatments indicate a growing market for Edwards' products.

Options pricing indicates higher volatility than historical averages, suggesting investor uncertainty.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how well Edwards can sustain its growth trajectory amidst increasing competition.

Bull Confirmed If

A revenue growth rate of over 10% would confirm strong demand and market expansion.

Bear Confirmed If

If revenue growth falls below 5%, it could indicate challenges in maintaining market share.

Pre-Earnings Positioning

Options Market

Implied Move

±5.93%

Historical Avg

±0.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±5.9% while EW has averaged ±0.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

32.1%

Calls (397K)P/C Ratio: 0.49Puts (340K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edwards beats expectations, history suggests a potential stock increase of around 0.96%, confirming strong demand.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors will look for management commentary on future growth.

Miss

A miss could result in a decline, with historical patterns indicating a potential drop of around 0.33%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth for heart valve therapies.
2Insights into upcoming product launches and their expected impact.
3Management's commentary on competitive pressures in the market.
4Updates on international market expansion efforts.
5Any changes to long-term guidance or strategic initiatives.